Company news

Jade Biosciences, Inc. (NASDAQ:JBIO) news

Jade Biosciences, Inc. news releases on 6ix. Latest, Sep 30, 2026: Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially…

Jade Biosciences, Inc. (NASDAQ:JBIO) news

Press releases & updates

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Jade Biosciences Announces Pricing of Public Offering of Common Stock

Jade Biosciences Announces Proposed Underwritten Public Offering

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy

Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jade Biosciences Announces $45 Million Private Placement

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement

Aerovate Therapeutics to Explore Strategic Alternatives

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference